Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SOSalman OtoukeshPKPaul KollerABAmanda Blackmon

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals worse survival linked to TP53 alterations and high-risk factors in leukemia populations.

Key Points

  • Overall survival at 2 years post-HCT was 45.6% for TP53-altered patients, highlighting the severity of these alterations.
  • Multivariable analysis confirmed that age ≥60 and high disease risk index independently predicted inferior outcomes.
  • Evaluation included patients with acute leukemia and MDS who underwent their first transplant, incorporating various prognostic variables.
  • Treatment approaches must address the challenges of TP53 alterations to improve long-term outcomes for these patients.

Cite This Study

Otoukesh et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e536https://doi.org/10.1182/blood-2025-2516
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  2. 2Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations
  3. 3Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations
  4. 4Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy2025
  5. 5Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT2025 · 1 citations